Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?

Liu DSK, Mato Prado M, Giovannetti E, Jiao LR, Krell J, Frampton AE.

Expert Rev Mol Diagn. 2019 Jun 10:1-6. doi: 10.1080/14737159.2019.1622414. [Epub ahead of print] No abstract available.

PMID:
31159604
2.

Pharmacogenetics of treatments for pancreatic cancer.

El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E.

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):437-447. doi: 10.1080/17425255.2019.1620731. Epub 2019 May 24. Review.

PMID:
31100206
3.

Rapid Induction of Liver Regeneration for Major Hepatectomy (REBIRTH): A Randomized Controlled Trial of Portal Vein Embolisation versus ALPPS Assisted with Radiofrequency.

Jiao LR, Fajardo Puerta AB, Gall TMH, Sodergren MH, Frampton AE, Pencavel T, Nagendran M, Habib NA, Darzi A, Pai M, Thomas R, Tait P.

Cancers (Basel). 2019 Mar 4;11(3). pii: E302. doi: 10.3390/cancers11030302.

4.

Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?

Gall TMH, Gerrard G, Frampton AE, Castellano L, Ahmad R, Habib N, Spalding D, Pai M, Foroni L, Jiao LR.

Oncotarget. 2019 Jan 22;10(7):696-706. doi: 10.18632/oncotarget.26511. eCollection 2019 Jan 22.

5.

Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma.

Gall TMH, Belete S, Khanderia E, Frampton AE, Jiao LR.

Am J Pathol. 2019 Jan;189(1):71-81. doi: 10.1016/j.ajpath.2018.03.020. Review.

PMID:
30558725
6.

Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.

Meijer LL, Garajová I, Caparello C, Le Large TYS, Frampton AE, Vasile E, Funel N, Kazemier G, Giovannetti E.

Ann Surg. 2018 Dec 9. doi: 10.1097/SLA.0000000000003084. [Epub ahead of print]

PMID:
30394883
7.

TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.

Ottaviani S, Stebbing J, Frampton AE, Zagorac S, Krell J, de Giorgio A, Trabulo SM, Nguyen VTM, Magnani L, Feng H, Giovannetti E, Funel N, Gress TM, Jiao LR, Lombardo Y, Lemoine NR, Heeschen C, Castellano L.

Nat Commun. 2018 May 10;9(1):1845. doi: 10.1038/s41467-018-03962-x.

8.

Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.

Frampton AE, Prado MM, López-Jiménez E, Fajardo-Puerta AB, Jawad ZAR, Lawton P, Giovannetti E, Habib NA, Castellano L, Stebbing J, Krell J, Jiao LR.

Oncotarget. 2018 Apr 10;9(27):19006-19013. doi: 10.18632/oncotarget.24873. eCollection 2018 Apr 10.

9.

A systematic review of gallstone sigmoid ileus management.

Farkas N, Kaur V, Shanmuganandan A, Black J, Redon C, Frampton AE, West N.

Ann Med Surg (Lond). 2018 Jan 31;27:32-39. doi: 10.1016/j.amsu.2018.01.004. eCollection 2018 Mar. Review.

10.

The density of mast cells c-Kit+ and tryptase+ correlates with each other and with angiogenesis in pancreatic cancer patients.

Ammendola M, Gadaleta CD, Frampton AE, Piardi T, Memeo R, Zuccalà V, Luposella M, Patruno R, Zizzo N, Gadaleta P, Pessaux P, Sacco R, Sammarco G, Ranieri G.

Oncotarget. 2017 Jul 31;8(41):70463-70471. doi: 10.18632/oncotarget.19716. eCollection 2017 Sep 19.

11.

miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma.

Puik JR, Meijer LL, Le Large TY, Prado MM, Frampton AE, Kazemier G, Giovannetti E.

Pharmacogenomics. 2017 Sep;18(14):1343-1358. doi: 10.2217/pgs-2017-0010. Epub 2017 Aug 23. Review.

PMID:
28832247
12.

Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer.

Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O, Peters GJ.

Semin Cancer Biol. 2017 Jun;44:43-59. doi: 10.1016/j.semcancer.2017.04.006. Epub 2017 Apr 22. Review.

13.

Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR.

Castellano L, Dabrowska A, Pellegrino L, Ottaviani S, Cathcart P, Frampton AE, Krell J, Stebbing J.

Nucleic Acids Res. 2017 May 5;45(8):4401-4412. doi: 10.1093/nar/gkx022.

14.

Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer.

Mato Prado M, Frampton AE, Giovannetti E, Stebbing J, Castellano L, Krell J.

Expert Rev Mol Diagn. 2016 Nov;16(11):1155-1162. Epub 2016 Oct 27. Review.

PMID:
27784183
15.

MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.

Miller HC, Frampton AE, Malczewska A, Ottaviani S, Stronach EA, Flora R, Kaemmerer D, Schwach G, Pfragner R, Faiz O, Kos-Kudła B, Hanna GB, Stebbing J, Castellano L, Frilling A.

Endocr Relat Cancer. 2016 Sep;23(9):711-26. doi: 10.1530/ERC-16-0044. Epub 2016 Jun 27.

16.

Oncological Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysis.

Giglio MC, Giakoustidis A, Draz A, Jawad ZAR, Pai M, Habib NA, Tait P, Frampton AE, Jiao LR.

Ann Surg Oncol. 2016 Oct;23(11):3709-3717. doi: 10.1245/s10434-016-5264-6. Epub 2016 Jun 8. Review.

17.

Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment.

Le Large TY, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, Giovannetti E.

Expert Rev Mol Diagn. 2016 Jul;16(7):733-6. doi: 10.1080/14737159.2016.1175940. Epub 2016 Apr 27. Review.

PMID:
27118062
18.

Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies.

Frampton AE, Krell J, Prado MM, Gall TM, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, Giovannetti E, Castellano L, Basyouny M, Habib NA, Kaltsidis H, Vlavianos P, Stebbing J, Jiao LR.

Oncotarget. 2016 May 10;7(19):28556-69. doi: 10.18632/oncotarget.8699.

19.

Gene of the month: HGF.

Fajardo-Puerta AB, Mato Prado M, Frampton AE, Jiao LR.

J Clin Pathol. 2016 Jul;69(7):575-9. doi: 10.1136/jclinpath-2015-203575. Epub 2016 Apr 12. Review.

20.

miR-515-5p controls cancer cell migration through MARK4 regulation.

Pardo OE, Castellano L, Munro CE, Hu Y, Mauri F, Krell J, Lara R, Pinho FG, Choudhury T, Frampton AE, Pellegrino L, Pshezhetskiy D, Wang Y, Waxman J, Seckl MJ, Stebbing J.

EMBO Rep. 2016 Apr;17(4):570-84. doi: 10.15252/embr.201540970. Epub 2016 Feb 10.

21.

Are we following an algorithm for managing chronic anal fissure? A completed audit cycle.

Farkas N, Solanki K, Frampton AE, Black J, Gupta A, West NJ.

Ann Med Surg (Lond). 2015 Nov 25;5:38-44. doi: 10.1016/j.amsu.2015.11.008. eCollection 2016 Feb.

22.

TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network.

Krell J, Stebbing J, Carissimi C, Dabrowska AF, de Giorgio A, Frampton AE, Harding V, Fulci V, Macino G, Colombo T, Castellano L.

Genome Res. 2016 Mar;26(3):331-41. doi: 10.1101/gr.191759.115. Epub 2015 Dec 23.

23.

International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer.

Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD; IAP/EPC study group on the clinical managements of pancreatic cancer.

Pancreatology. 2016 Jan-Feb;16(1):14-27. doi: 10.1016/j.pan.2015.10.013. Epub 2015 Nov 12. Review.

PMID:
26699808
24.

MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.

Garajová I, Funel N, Fiorentino M, Agostini V, Ferracin M, Negrini M, Frassineti GL, Gavelli G, Frampton AE, Biasco G, Giovannetti E.

Clin Epigenetics. 2015 Dec 16;7:129. doi: 10.1186/s13148-015-0162-5. eCollection 2015.

25.

Single-cell sequencing in cancer research.

Mato Prado M, Frampton AE, Stebbing J, Krell J.

Expert Rev Mol Diagn. 2016;16(1):1-5. doi: 10.1586/14737159.2016.1115345. Epub 2015 Nov 23.

PMID:
26594792
26.

Circulating microRNAs as diagnostic biomarkers for pancreatic cancer.

Le Large TY, Meijer LL, Prado MM, Kazemier G, Frampton AE, Giovannetti E.

Expert Rev Mol Diagn. 2015;15(12):1525-9. doi: 10.1586/14737159.2015.1112273. Epub 2015 Nov 15.

PMID:
26567751
27.

Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression.

Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TM, Ahmad R, Habib NA, Knösel T, Stebbing J, Jiao LR.

Lancet. 2015 Feb 26;385 Suppl 1:S37. doi: 10.1016/S0140-6736(15)60352-X.

PMID:
26312859
28.

The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network.

Krell J, Stebbing J, Frampton AE, Carissimi C, Harding V, De Giorgio A, Fulci V, Macino G, Colombo T, Castellano L.

Lancet. 2015 Feb 26;385 Suppl 1:S15. doi: 10.1016/S0140-6736(15)60330-0.

PMID:
26312837
29.

Gene of the month: NANOG.

Mato Prado M, Frampton AE, Stebbing J, Krell J.

J Clin Pathol. 2015 Oct;68(10):763-5. doi: 10.1136/jclinpath-2015-203238. Epub 2015 Jul 27. Review. No abstract available.

PMID:
26216907
30.

microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis.

Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing J.

Eur J Cancer. 2015 Jul;51(11):1389-404. doi: 10.1016/j.ejca.2015.04.006. Epub 2015 May 19. Review.

PMID:
26002251
31.

Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis.

Roca-Alonso L, Castellano L, Mills A, Dabrowska AF, Sikkel MB, Pellegrino L, Jacob J, Frampton AE, Krell J, Coombes RC, Harding SE, Lyon AR, Stebbing J.

Cell Death Dis. 2015 May 7;6:e1754. doi: 10.1038/cddis.2015.89.

32.

Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis.

Le Large TY, Frampton AE, Meijer LL, Stebbing J, Kazemier G, Giovannetti E.

Am J Gastroenterol. 2015 May;110(5):768-9. doi: 10.1038/ajg.2015.77. No abstract available.

PMID:
25942302
33.

Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.

Frampton AE, Stebbing J, Gall TM, Silver B, Jiao LR, Krell J.

Expert Rev Mol Diagn. 2015 Mar;15(3):325-8. doi: 10.1586/14737159.2015.1002771. Epub 2015 Feb 6.

PMID:
25656048
34.

Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.

Alshaker H, Krell J, Frampton AE, Waxman J, Blyuss O, Zaikin A, Winkler M, Stebbing J, Yagüe E, Pchejetski D.

Breast Cancer Res. 2014 Oct 25;16(5):426. doi: 10.1186/s13058-014-0426-6.

35.

Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer.

Alshaker H, Wang Q, Frampton AE, Krell J, Waxman J, Winkler M, Stebbing J, Cooper C, Yagüe E, Pchejetski D.

Breast Cancer Res Treat. 2015 Jan;149(1):59-67. doi: 10.1007/s10549-014-3228-8. Epub 2014 Dec 7.

PMID:
25481644
36.

A Study of Clinical Coding Accuracy in Surgery: Implications for the Use of Administrative Big Data for Outcomes Management.

Nouraei SA, Hudovsky A, Frampton AE, Mufti U, White NB, Wathen CG, Sandhu GS, Darzi A.

Ann Surg. 2015 Jun;261(6):1096-107. doi: 10.1097/SLA.0000000000000851.

PMID:
25470740
37.

The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.

Badreldin W, Krell J, Chowdhury S, Harland SJ, Mazhar D, Harding V, Frampton AE, Wilson P, Berney D, Stebbing J, Shamash J.

BJU Int. 2016 Mar;117(3):418-23. doi: 10.1111/bju.13004. Epub 2015 Jun 13.

38.

Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.

Garajová I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E.

Biomed Res Int. 2014;2014:678401. doi: 10.1155/2014/678401. Epub 2014 Aug 28. Review.

39.

miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.

Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, Castellano L, Galla V, Peters GJ, Giovannetti E.

Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):384-93. doi: 10.1080/15257770.2014.891741.

PMID:
24940696
40.

The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁.

Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y, Frampton AE, Green AR, Ellis IO, Ali S, Lenz HJ, Thanou M, Stebbing J, Giamas G.

Sci Signal. 2014 Jun 17;7(330):ra58. doi: 10.1126/scisignal.2005170.

PMID:
24939894
41.

Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer.

Krell J, Frampton AE, Mirnezami R, Harding V, De Giorgio A, Roca Alonso L, Cohen P, Ottaviani S, Colombo T, Jacob J, Pellegrino L, Buchanan G, Stebbing J, Castellano L.

PLoS One. 2014 Jun 13;9(6):e98561. doi: 10.1371/journal.pone.0098561. eCollection 2014.

42.

Radio-frequency-assisted Liver Partition with Portal vein ligation (RALPP) for liver regeneration.

Gall TM, Sodergren MH, Frampton AE, Fan R, Spalding DR, Habib NA, Pai M, Jackson JE, Tait P, Jiao LR.

Ann Surg. 2015 Feb;261(2):e45-6. doi: 10.1097/SLA.0000000000000607. No abstract available.

PMID:
24670841
43.

miR-15b and miR-17 Are Tumor-derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia.

Frampton AE, Krell J, Gall TM, Castellano L, Stebbing J, Jiao LR.

Ann Surg. 2015 Aug;262(2):e61-2. doi: 10.1097/SLA.0000000000000605. No abstract available.

PMID:
24646542
44.

Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer.

Gall TM, Jacob J, Frampton AE, Krell J, Kyriakides C, Castellano L, Stebbing J, Jiao LR.

JAMA Surg. 2014 May;149(5):482-5.

PMID:
24599353
45.

A microRNA meta-signature for pancreatic ductal adenocarcinoma.

Frampton AE, Giovannetti E, Jamieson NB, Krell J, Gall TM, Stebbing J, Jiao LR, Castellano L.

Expert Rev Mol Diagn. 2014 Apr;14(3):267-71. doi: 10.1586/14737159.2014.893192. Epub 2014 Feb 28.

PMID:
24575833
46.

Surgical techniques for improving outcomes in pancreatic ductal adenocarcinoma.

Gall TM, Thompson Z, Dinneen EP, Sodergren M, Pai M, Frampton AE, Jiao LR.

Expert Rev Gastroenterol Hepatol. 2014 Mar;8(3):241-6. doi: 10.1586/17474124.2014.881251. Epub 2014 Feb 4. Review.

PMID:
24491183
47.

Neoadjuvant chemotherapy and primary-first approach for rectal cancer with synchronous liver metastases.

Gall TM, Basyouny M, Frampton AE, Darzi A, Ziprin P, Dawson P, Paraskeva P, Habib NA, Spalding DR, Cleator S, Lowdell C, Jiao LR.

Colorectal Dis. 2014 Jun;16(6):O197-205. doi: 10.1111/codi.12534.

PMID:
24344746
48.

Challenges facing in vivo tracking of mesenchymal stem cells used for tissue regeneration.

Hossain MA, Frampton AE, Bagul A.

Expert Rev Med Devices. 2014 Jan;11(1):9-13. doi: 10.1586/17434440.2014.865306. Epub 2013 Nov 26.

PMID:
24308739
49.

IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.

Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C.

Future Oncol. 2013 Dec;9(12):1923-35. doi: 10.2217/fon.13.143. Review.

50.

Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: has progress been made?

Gall TM, Frampton AE, Krell J, Habib NA, Castellano L, Stebbing J, Jiao LR.

Future Oncol. 2013 Dec;9(12):1861-9. doi: 10.2217/fon.13.152. Review.

PMID:
24295416

Supplemental Content

Loading ...
Support Center